Compounded Tirzepatide vs Mounjaro/Zepbound: Differences

"Compounded tirzepatide" and the brand products Mounjaro and Zepbound all contain the same active molecule, but they are not the same product. They differ in how they are made, who oversees them, how concentrated they are and what they cost. This is a neutral, third-person look at those differences so the numbers and the labels mean the same thing to everyone reading them.

None of this is dosing guidance. Tirzepatide in research or compounded form is a research compound, not an FDA-approved finished drug, and any protocol decision belongs with a licensed clinician. Where math comes up, the tirzepatide calculator and the reconstitution calculator handle the conversions so the figures stay consistent.

Same molecule, three different products

Tirzepatide is a single peptide, a dual GLP-1 and GIP receptor agonist. Mounjaro and Zepbound are two brand names for the same molecule sold by the same manufacturer, with Mounjaro and Zepbound marketed for different approved uses. Compounded tirzepatide is the same peptide prepared by a compounding pharmacy or supplied as a research lyophilized powder, outside the branded finished product.

• Mounjaro / Zepbound: FDA-approved, single source manufacturer, fixed prefilled pens or single-dose vials.
• Compounded tirzepatide: prepared per order or sold as powder; the pharmacy or supplier sets the form and strength.
• Research powder: shipped lyophilized, requires reconstitution before any volume is measured.

FDA status: the core difference

Brand tirzepatide is FDA-approved, meaning each lot is made under reviewed manufacturing standards and the strength on the label is verified. Compounded versions are not FDA-approved as finished products. Compounding is permitted under specific rules, but the agency does not review individual compounded batches the same way.

This matters because tirzepatide was on the FDA shortage list, which temporarily widened compounding. Once a drug leaves the shortage list, the rules around large-scale compounding tighten. Status can change, so the regulatory picture for any compounded source is not fixed. Research-grade powder sold "not for human use" sits outside the approved supply chain entirely.

Concentration variability is where the math breaks

Brand pens deliver a fixed amount per click or per dose, so the user never measures anything. Compounded and research tirzepatide do not work that way. A compounded vial might be 10 mg, 20 mg, or another total, and a research vial states only the total powder, not a concentration. Concentration only exists after you add liquid.

Two vials with the same milligram total can give very different unit counts depending on how much bacteriostatic water is added. Worked example with a 10 mg vial:

• 10 mg + 1 mL water = 10 mg/mL. A 2.5 mg amount is 0.25 mL, which is 25 units on a U-100 insulin syringe.
• 10 mg + 2 mL water = 5 mg/mL. The same 2.5 mg amount is now 0.5 mL, or 50 units.
• Same vial, same target, double the units, because only the dilution changed.

That is the single biggest reason compounded and research tirzepatide cannot copy a brand pen's numbers. The mg are fixed; the units depend on the water. See tirzepatide units per dose for a full unit table, and how many units is 2.5mg tirzepatide for that exact case.

Salt forms and formulation

Brand tirzepatide uses a defined formulation with set buffers and a known purity. Compounded products can vary. One point that has drawn attention is the use of salt forms, such as tirzepatide acetate or other salts, instead of the base peptide. A salt form is not identical to the molecule in the approved product, and some compounded preparations have been flagged for using them.

• Brand: consistent formulation, stated purity, fixed excipients.
• Compounded: formulation set by the pharmacy; salt form and purity may differ by source.
• Research powder: purity stated on a certificate of analysis if one is provided; quality is source dependent.

Cost

Cost is often the reason people compare these at all. Brand pens carry a list price in the four-figure-per-month range before insurance or savings programs. Compounded versions are typically marketed at a lower monthly figure. Research powder is usually cheapest per milligram, but it carries no clinical oversight, no guaranteed purity, and the labor of reconstitution falls on the user.

Lower price tracks with less verification and more user responsibility. The cheaper the source, the more the burden of measuring, diluting and storing correctly shifts to whoever holds the vial.

Quick comparison

• Active molecule: identical across all three.
• FDA approval: brand yes; compounded and research no.
• Dose form: brand is fixed pen or vial; compounded and research need reconstitution and measuring.
• Concentration: brand fixed; compounded and research depend on added water.
• Formulation: brand defined; compounded and research can vary, including salt forms.
• Cost: brand highest, compounded lower, research powder lowest.

If you are doing the math yourself

The moment a product is not a fixed brand pen, the user owns the conversion. Reconstitute, fix the concentration, then convert the target milligram amount into syringe units at that concentration. The tirzepatide calculator does this end to end, and tirzepatide dosage chart lists common reference amounts. Keep records and read the full disclaimer: these are research compounds, and a clinician should make any actual decision.